ArticlePloS one2025
Special histological subtypes of breast cancer in a Hispanic Latino population.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSpecial histologic subtypes of breast cancer have a unique biological behavior and outcomes. The literature has demonstrated that histologic and phenotype subclassification of breast cancer varies according to race and populations. Our aim was to describe the clinicopathological characteristics and outcomes of breast cancer with special histological subtypes in a Latin/Hispanic population.
methodsA retrospective study was conducted. We reviewed the medical records of patients newly diagnosed with special histological subtypes of breast cancer at a single tertiary reference cancer center in Peru from 2014 to 2019.
resultsA total of 479 patients were included, the median age at diagnosis was 55 years (range 26-89). The majority of patients were from a metropolitan area (59.1%). The most common histological subtype was lobular (34.9%), followed by mucinous (12.7%), papillary (12.5%), apocrine (6.9%), metaplastic (5.4%), medullary (3.8%), cribriform (3.3%), neuroendocrine (0.8%), and 9.2% mixed histology. 61.6% had a moderately differentiated grade. The most common phenotype at diagnosis was HR + HER2- (57.7%), followed by triple-negative breast cancer (TNBC)(13.2%), showing a similar pattern after neoadjuvant therapy (NAT); HR + HER- (61.7%), and TNBC (16.3%). At diagnosis most patients were stage T2 (40.3%), N0 (61.0%) and stage II (40.7%); while after NAT, stage I (64.7%) was the most common. In regard to NAT, 45.9% received chemotherapy, 31.5% hormone therapy, 15.7% trastuzumab, and 5.8% radiotherapy. The majority underwent mastectomy (71.4%). In relation to adjuvant treatment, 72.7% received chemotherapy, 74.1% hormone therapy, 9.4% trastuzumab, and 76.4% radiotherapy. Loco-regional and distant recurrence occurred in 4.2% and 12.7%, respectively. With a median follow-up of 97 months (8 years), the overall survival (OS) at 5 years was 82%, with patients with cribriform histology presenting the best rate (100%) compared to the worst observed in patients with metaplastic histology (54%).
conclusionsThe most frequent special histologic subtypes of breast cancer in Latino-Hispanic patients were lobular, mucinous, papillary, metaplastic, and apocrine carcinomas. Patients were diagnosed at more advanced stages and more frequently presented a TNBC phenotype compared to the non-Hispanic White population. Certain histological subtypes in our population presented worse OS rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.